Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Key Features of New USP <787>

By R&D Editors | February 4, 2016

The new regulation accepts that the presence of insoluble protein particles is an intrinsic part of protein-based therapies and labels these naturally occurring particles as “inherent” particles. It differentiates between these inherent protein particles and those “contaminating” particles that should not be present. It goes further and sub divides the latter into: 

• Extrinsic particles: those that are added to or fall into the drug product from an external source, such as the air.
• Intrinsic particles: those already present in the drug container before it is filled with the drug product. This may come from ineffective cleaning processes or as a result of potential aggregation of the drug compound itself over time.

Both USP chapters <788> and <787> require the manufacturer to test for particles at ≥10 micron and ≥25 micron in size. Typically the inherent protein particles are in the sub-micron, nanometer size range and are not, therefore, detected by the tests. However, a common feature of protein-based therapies is the tendency of the proteins to group together, or aggregate, over time. Because of this, protein aggregations are likely to form large enough particles to have an impact on the pass or fail result of the USP <787> or <788> test. Protein aggregation is also undesirable from a drug efficacy point of view as aggregation causes the therapeutic part of the protein to become occluded, making it less effective. For the patient, this means that the normal dosage may no longer work and their condition would therefore deteriorate.


This cleanroom tip was taken from “USP <787> for Subvisible Liquid” by Tony Harrison. The article originally appeared in the November/December 2015 issue of Controlled Environments.

Related Articles Read More >

Specialty transfer systems spelled out in safety data sheets (SDS) guidelines
Safe coronavirus research with Systec autoclaves
Lightning protection for laboratories prevents lost research and equipment
Study finds doctor-pharmacist partnership significantly reduces patient harm
Study finds doctor-pharmacist partnership significantly reduces patient harm
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars